SAN FRANCISCO, 23rd September 2022- Surge, a pioneer in biotech and medical AI, announced a USD 2.6 million round co-led by Boutique Venture Partners, a top Silicon Valley firm, and HCVC, a worldwide early-stage fund focused on high-potential technology startups. Nicolas Godin, the COO/CFO of Cardiologs, and several seasoned angel investors took part in the round. The 2022 iLab grant was given to Surge together with other non-dilutive grants to finish raising money.
Surge’s primary product uses cutting-edge machine learning algorithms to decode a patient’s immune system from a blood sample. It is supported in Europe by Agoranov, 50 Partners, and Wilco, in addition to being hosted in the US by nonprofit entrepreneurs, StartX. With this technology, doctors may now predict postoperative issues with great speed. Given that 40% of patients aged 65 and older experience long-lasting cognitive effects following orthopedic or cardiac surgery and that 30% of major surgeries currently end in complications, Surge’s solution enables targeted and personalized interventions to lower patients’ risk of post-surgical complications.
Surge has acquired the exclusive license to the patented postoperative complication prediction technology from Stanford University. Surge also formed a research partnership with Stanford in the summer of 2022 intending to create biotech advancements.
Surge will be able to expand its team thanks to the investment round and carry out clinical trials with other hospitals, like the one it began in the spring of 2022 with the Foch Hospital in Suresnes, France. The Foch research will confirm Surge’s prediction of surgical site infections in abdominal surgery when it begins in the spring of 2022.
Julien Hédou, co-founder and president of Surge:
“Our goal is to create the go-to surgical precision medicine solution. With the aid of immune profiling techniques, we intend to broaden and diversify the uses of our technology for all surgical problems. In the future, we hope to incorporate our approach into more therapeutic fields.”
Surge is dedicated to enhancing surgical patients’ care. Our multidisciplinary team has developed a diagnostic to recognize people at risk for problems. This breakthrough will alter the patient experience and change the accepted standard of surgical treatment by identifying surgical risks in advance to enable customisation of the care pathway. Our group has the same goal regarding healthcare innovation: creating patient-centered solutions that are advantageous to the entire healthcare system.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
